Pedro P LÃ³pez-Casas

List of Publications by Year
in descending order

45 papers	2,186 citations	236925 25 h-index	243625 44 g-index
46 all docs	46 docs citations	46 times ranked	4727 citing authors

#	Article	IF	Citations
1	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. British Journal of Cancer, 2021, 124, 552-563.	6.4	63
2	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. European Journal of Cancer, 2021, 147, 74-83.	2.8	42
3	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers, 2021, 13, 2334.	3.7	9
4	Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Science Translational Medicine, 2020, 12, .	12.4	77
5	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic antiâ€“PD-1 for patients with antiâ€“PD-1â€“refractory tumors. Science Translational Medicine, 2020, 12, .	12.4	51
6	Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells. Molecular Cancer Therapeutics, 2020, 19, 1751-1760.	4.1	31
7	OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clinical Cancer Research, 2020, 26, 3420-3430.	7.0	47
8	CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell, 2020, 37, 340-353.e6.	16.8	114
9	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
10	A multifunctional drug nanocarrier for efficient anticancer therapy. Journal of Controlled Release, 2019, 294, 154-164.	9.9	29
11	c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer Cell, 2018, 33, 217-228.e4.	16.8	93
12	Personalized RNA Medicine for Pancreatic Cancer. Clinical Cancer Research, 2018, 24, 1734-1747.	7.0	67
13	A Tricin Derivative from <i>Deschampsia antarctica</i> Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response. Molecular Cancer Therapeutics, 2018, 17, 966-976.	4.1	21
14	MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management. Contrast Media and Molecular Imaging, 2018, 2018, 1-13.	0.8	13
15	PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. Genome Medicine, 2018, 10, 41.	8.2	63
16	Afatinib restrains K-RASâ€“driven lung tumorigenesis. Science Translational Medicine, 2018, 10, .	12.4	99
17	Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. Public Health Genomics, 2017, 20, 81-91.	1.0	10
18	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clinical Cancer Research, 2017, 23, 6661-6672.	7.0	110

#	ARTICLE	IF	CITATIONS
19	Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget, 2017, 8, 35289-35300.	1.8	51
20	Lurbinectedin induces depletion of tumor-associated macrophages (TAM), an essential component of its <i>in vivo</i> synergism with gemcitabine. DMM Disease Models and Mechanisms, 2016, 9, 1461-1471.	2.4	21
21	Monitoring vascular normalization induced by antiangiogenic treatment with 18Fâ€fluoromisonidazoleâ€PET. Molecular Oncology, 2016, 10, 704-718.	4.6	36
22	SPARC-Independent Delivery of <i>Nab</i>-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Molecular Cancer Therapeutics, 2016, 15, 680-688.	4.1	49
23	Cell-free circulating tumour DNA as a tool for monitoring response to anti-EGFR therapies of mCCR.. Journal of Clinical Oncology, 2016, 34, e23059-e23059.	1.6	0
24	SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Clinical Cancer Research, 2015, 21, 4811-4818.	7.0	117
25	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Investigational New Drugs, 2015, 33, 710-719.	2.6	24
26	Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. PLoS ONE, 2015, 10, e0142631.	2.5	28
27	Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors. Oncotarget, 2015, 6, 8539-8551.	1.8	31
28	Reply: â€˜Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancerâ€™. British Journal of Cancer, 2014, 111, 1677-1678.	6.4	2
29	Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. Pharmacology Research and Perspectives, 2014, 2, e00067.	2.4	14
30	Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. Nature Medicine, 2014, 20, 1230-1231.	30.7	8
31	Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Medicine, 2014, 6, 27.	8.2	41
32	Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clinical Cancer Research, 2014, 20, 2476-2484.	7.0	140
33	Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. British Journal of Cancer, 2013, 109, 926-933.	6.4	251
34	Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. Journal of Clinical Oncology, 2012, 30, e45-e48.	1.6	79
35	An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. Proteomics, 2012, 12, 1319-1327.	2.2	22
36	The effects of different endocrine disruptors defining compound-specific alterations of gene expression profiles in the developing testis. Reproductive Toxicology, 2012, 33, 106-115.	2.9	39

#	Article	IF	Citations
37	Gene-expression profiling in pancreatic cancer. Expert Review of Molecular Diagnostics, 2010, 10, 591-601.	3.1	30
38	Gene silencing by RNAi in mouse Sertoli cells. Reproductive Biology and Endocrinology, 2008, 6, 29.	3.3	18
39	The expression patterns of genes involved in the RNAi pathways are tissue-dependent and differ in the germ and somatic cells of mouse testis. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2008, 1779, 306-311.	1.9	49
40	New scaffolds for the design of selective estrogen receptor modulators. Organic and Biomolecular Chemistry, 2008, 6, 3486.	2.8	24
41	Phosphoprotein enriched in astrocytes-15 is expressed in mouse testis and protects spermatocytes from apoptosis. Reproduction, 2007, 133, 743-751.	2.6	13
42	Changes in Vinexin Expression Patterns in the Mouse Testis Induced by Developmental Exposure to 17Beta-Estradiol1. Biology of Reproduction, 2007, 77, 605-613.	2.7	9
43	Expression of stress inducible protein 1 (Stip1) in the mouse testis. Molecular Reproduction and Development, 2006, 73, 1361-1366.	2.0	15
44	Regulation of flotillin-1 in the establishment of NIH-3T3 cell-cell interactions1. FEBS Letters, 2003, 555, 223-228.	2.8	15
45	Ran GTPase expression during early development of the mouse embryo. Mechanisms of Development, 2002, 113, 103-106.	1.7	8